Dyadic International Inc DYAI
We take great care to ensure that the data presented and summarized in this overview for DYADIC INTERNATIONAL INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding DYAI
View all-
Bandera Partners LLC New York, NY1.57MShares$2.68 Million0.62% of portfolio
-
Chapin Davis, Inc. Baltimore, MD868KShares$1.48 Million0.29% of portfolio
-
Vanguard Group Inc Valley Forge, PA806KShares$1.38 Million0.0% of portfolio
-
Northeast Financial Consultants Inc Westport, CT250KShares$427,5000.01% of portfolio
-
Black Rock Inc. New York, NY249KShares$426,1060.0% of portfolio
-
Geode Capital Management, LLC Boston, MA240KShares$410,6990.0% of portfolio
-
Sage Mountain Advisors LLC107KShares$182,2240.01% of portfolio
-
Susquehanna International Group, LLP Bala Cynwyd, PA87KShares$148,7610.0% of portfolio
-
High Tower Advisors, LLC Chicago, IL79.6KShares$136,0620.0% of portfolio
-
Northern Trust Corp Chicago, IL72.9KShares$124,7010.0% of portfolio
Latest Institutional Activity in DYAI
Top Purchases
Top Sells
About DYAI
Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States. The company utilizes its patented and proprietary C1 platform and other technologies to conduct research, development, and commercial activities for the development and manufacturing of human and animal vaccines and drugs, such as virus like particles and antigens, monoclonal antibodies, bi/tri-specific antibodies, fab antibody fragments, Fc-fusion proteins, biosimilars and/or biobetters, and other therapeutic enzymes and proteins. It offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial, is to validate to serve as proof of concept for the development of next generation multivariant COVID-19 vaccine candidates. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; strategic research services agreement with Biotechnology Developments for Industry in Pharmaceuticals, S.L.U.; and collaboration with Syngene International Limited. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.
Insider Transactions at DYAI
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 22
2024
|
Michael P. Tarnok Director |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+4.87%
|
$0
$0.97 P/Share
|
|
Jun 11
2024
|
Barry Buckland Director |
BUY
Exercise of conversion of derivative security
|
Direct |
11,793
+23.23%
|
$11,793
$1.59 P/Share
|
|
May 21
2024
|
Michael P. Tarnok Director |
SELL
Payment of exercise price or tax liability
|
Direct |
24,431
-9.93%
|
$24,431
$1.67 P/Share
|
|
May 21
2024
|
Michael P. Tarnok Director |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+4.02%
|
$30,000
$1.36 P/Share
|
|
Mar 13
2024
|
Joseph P Hazelton Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
41,720
+29.61%
|
-
|
|
Mar 13
2024
|
Ronen Tchelet VP of Research and Bus. Dvlpmt |
BUY
Grant, award, or other acquisition
|
Direct |
11,169
+31.89%
|
-
|
|
Mar 13
2024
|
Ping Wang Rawson Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
35,366
+22.73%
|
-
|
|
Mar 13
2024
|
Mark A Emalfarb President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
124,454
+2.6%
|
-
|
|
Jan 03
2024
|
Arindam Bose Director |
BUY
Exercise of conversion of derivative security
|
Direct |
27,174
+50.0%
|
-
|
|
Jan 03
2024
|
Jack Kaye Director |
BUY
Exercise of conversion of derivative security
|
Direct |
27,174
+44.73%
|
-
|
|
Jan 03
2024
|
Michael P. Tarnok Director |
BUY
Exercise of conversion of derivative security
|
Direct |
27,174
+11.17%
|
-
|
|
Jan 03
2024
|
Seth Herbst Director |
BUY
Exercise of conversion of derivative security
|
Direct |
27,174
+17.05%
|
-
|
|
Jan 03
2024
|
Barry Buckland Director |
BUY
Exercise of conversion of derivative security
|
Direct |
27,174
+50.0%
|
-
|
|
Jan 03
2024
|
Patrick K. Lucy Director |
BUY
Exercise of conversion of derivative security
|
Direct |
27,174
+50.0%
|
-
|
|
Jan 03
2023
|
Joseph P Hazelton Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
57,448
+50.0%
|
$57,448
$1.38 P/Share
|
|
Jan 03
2023
|
Mark A Emalfarb President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
138,478
+2.96%
|
$138,478
$1.38 P/Share
|
|
Jan 03
2023
|
Ping Wang Rawson Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
39,351
+31.68%
|
$39,351
$1.38 P/Share
|
|
Jan 03
2023
|
Ronen Tchelet VP of Research and Bus. Dvlpmt |
BUY
Grant, award, or other acquisition
|
Direct |
12,684
+50.0%
|
$12,684
$1.38 P/Share
|
|
Jul 08
2022
|
Ronen Tchelet VP of Research and Bus. Dvlpmt |
SELL
Open market or private sale
|
Direct |
1,089
-100.0%
|
$3,267
$3.41 P/Share
|
|
Jul 08
2022
|
Ronen Tchelet VP of Research and Bus. Dvlpmt |
BUY
Exercise of conversion of derivative security
|
Direct |
1,089
+50.0%
|
$1,089
$1.57 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 213K shares |
|---|---|
| Exercise of conversion of derivative security | 230K shares |
| Payment of exercise price or tax liability | 24.4K shares |
|---|